{
  "docId": "019de071-b74f-770c-80cd-22f6f746fca1",
  "docSlug": "da6e8db4dad70fc7ff4e589a15b2ab41",
  "documentTitle": "BioNTech | Results Presentation Deck | 40 slides",
  "authorId": "biontech",
  "authorName": "BioNTech",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 20,
  "pageCount": 40,
  "prevPage": 19,
  "nextPage": 21,
  "slideType": "problem_statement",
  "function": "diagnose_problem",
  "density": "overcrowded",
  "nDataPoints": 5,
  "notes": "Includes a process flow diagram illustrating the current standard of care and patient outcomes.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-b74f-770c-80cd-22f6f746fca1/20",
  "deckHref": "/decks/019de071-b74f-770c-80cd-22f6f746fca1",
  "deckJsonHref": "/decks/019de071-b74f-770c-80cd-22f6f746fca1.json",
  "deckAnchorHref": "/decks/019de071-b74f-770c-80cd-22f6f746fca1#slide-20",
  "components": [
    {
      "bbox": {
        "h": 0.06,
        "w": 0.92,
        "x": 0.04,
        "y": 0.57
      },
      "kind": "callout",
      "text": "Challenge in Adjuvant Setting in Stage 2 (high risk) and Stage 3 Colorectal Cancer: Residual cancer cells may remain.",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "986fd373-e91d-453d-8062-322f2502f136",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.55,
        "x": 0.04,
        "y": 0.65
      },
      "kind": "diagram",
      "text": "Stage II (high risk) and Stage III colorectal cancer -> Surgery -> CT scan -> Adjuvant chemo given to all patients",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "29dc2533-dea7-4ddb-b163-43f15e04e9d7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.9,
        "x": 0.06,
        "y": 0.3
      },
      "kind": "list",
      "text": "Colorectal cancer is second deadliest cancer worldwide, 5 year OS in regional disease is 71%. SoC in Stage II (high risk) and Stage III CRC after removal of the primary tumor and adjuvant chemotherapy is watchful waiting. ctDNA is a marker for minimal residual disease and thus can identify patients at high risk of disease recurrence. In ctDNA-positive, Stage 2 (high risk) and Stage 3 CRC post AdCTx, duration of disease free survival is 6 months",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0eb60460-7e65-433c-8eac-96db4795b68f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.6,
        "x": 0.04,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "OS, Overall Survival; CRC, Colorectal Cancer; SoC, Standard of Care; ctDNA, circulating tumor DNA; AdCTx, adjuvant chemotherapy. 1WHO factsheet on cancer. 2018; 2Seer database; 3Fan et al, PLoS One 2017; 4Loupakis et al. 2021, JCO Precision Oncology; 5Reinert et al., JAMA Oncology, 2019",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3067f652-9ac3-4a3e-a285-bda67cffa0f3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.92,
        "x": 0.04,
        "y": 0.18
      },
      "kind": "subtitle",
      "text": "Randomized, Phase 2 trial evaluating autogene cevumeran* in the adjuvant treatment of circulating tumor DNA positive, surgically resected Stage II (high risk)/Stage III colorectal cancer",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "283a8d5d-f82e-4513-b9f4-2f95a66f4861",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.36,
        "x": 0.6,
        "y": 0.65
      },
      "kind": "table",
      "text": "No Residual Disease: 50% Cured by surgery alone. Microscopic Residual Disease: 20% Cured by chemo on top of surgery, 30% Recur despite surgery + chemo",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cd93459b-cf0b-47e3-a27c-94c469bb8f3c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.04,
        "y": 0.05
      },
      "kind": "title",
      "text": "Autogene cevumeran (BNT122): First Patient Dosed in Phase 2 Clinical Trial in Adjuvant Colorectal Cancer",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ccb6db9c-ed17-4219-b021-9450f7664ae1",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Before-After-Bridge",
      "slug": "before-after-bridge",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "838c8064-dceb-461e-a318-cf09a2dc5cbd",
      "evidence": "The slide shows a process flow from 'Surgery' to 'CT scan' to 'Adjuvant chemo', which could be related to a before-after bridge.",
      "confidence": 0.6
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 11,
      "beatId": "3ef0a596-8c25-4f98-9ce3-ac572ab324b0",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The presentation provides key messages and takeaways on COVID-19 vaccine reach and therapeutic modalities",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 6,
      "name": "Logic Chain",
      "slug": "01-logic-chain",
      "bestFor": "Skeptical audiences, controversial recommendations, rigorous analysis",
      "matchId": "e3928016-4f85-43ef-b051-6dae022547eb",
      "evidence": "The presentation provides a clear logic chain of performance and pipeline growth",
      "position": 0,
      "objective": "To demonstrate BioNTech's strong performance and pipeline expansion",
      "structure": "Premise 1 (Accepted truth) -> Premise 2 (Observed fact) -> Therefore... (Inevitable conclusion)",
      "confidence": 0.7,
      "description": "Build an airtight chain of logic where each premise leads inevitably to the conclusion"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}